Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-T Meeting 2020 | Translation from academia to industry: manufacturing of CAR T-cells

Bruce Levine • 30 Jan 2020
CAR-T Meeting 2020
Acute Lymphoblastic Leukemia Diffuse Large B-Cell Lymphoma Leukemia Lymphoma Non-Hodgkin Lymphoma CAR-T Tisagenlecleucel

Bruce Levine, PhD, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, outlines the translation from academia CAR T-cell manufacturing to industry. Dr Levine shares his experience on how academia and industry can collaborate to develop innovative CAR T-cells. This interview took place at the 2nd European CAR T-Cell Meeting in Sitges, Spain.

More from Bruce Levine

1:26
The impact of COVID-19 on CAR-T therapy
Bruce Levine • 28 May 2020
1:15
CAR-T therapy: where is it going?
Bruce Levine • 28 May 2020
1:20
ISCT 2020: Moving ahead at full speed session - what can delegates look forward to?
Bruce Levine • 28 May 2020
1:00
ISCT 2020: looking forward to advances and emerging technologies in immune-mediated cancer therapy
Bruce Levine • 28 May 2020

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
1:15
Comparing the efficacy of salvage therapies in adult B-ALL: a retrospective real-world study
Alex Rampotas • 16 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
3:34
Total marrow and lymphoid irradiation plus cyclophosphamide & etoposide in poor-risk acute leukemias
Anthony Stein • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals